Dear supporter,

I am pleased to present to you the 2014 Mesothelioma Applied Research Foundation’s annual report, including its audited financials. This organization, its leadership, board of directors, science advisory board, and staff are all dedicated to maintaining the highest level of accountability and transparency, a trait we believe sets us apart from the rest.

Our effort in this regard continues to be acknowledged through third-party charity evaluators who this year, as in years past, gave us the highest grades and accolades. You can read more about it on page 4 of this publication.

Some of the highlights of working toward our mission in 2014 include reaching $9 million in total awards granted through our research program. Our education and patient support program has been more popular than ever. In fact, by the end of 2014, we saw a jump in demand of services of 44%.

In 2014, we held three conferences – our usual annual Symposium was once again a main destination for members of the mesothelioma community with 250 members attending. This year’s Symposium was also unique because, for the first time, it provided a unique session organized for clinicians and researchers to facilitate collaboration and information-sharing, which within the field of mesothelioma has been traditionally difficult to accomplish. Our conferences also took us to Philadelphia and Chicago, where we focused on showcasing local experts and their specialty areas.

Funding for mesothelioma, as for other diseases and causes, has been more and more difficult to achieve. In 2014, we also saw certain donations decrease, however with over 65% of our funding coming from individuals, we are proud of our community’s participation in our common mission to end mesothelioma.

Across the following page, you will find in more detail, information about our work – I invite you to read through these pages and know that these accomplishments would not be possible without your steady support.

With gratitude,

Melinda Kotzian, Chief Executive Officer
Mesothelioma Applied Research Foundation
BOARD OF DIRECTORS
Volunteer members of the Meso Foundation’s board of directors are responsible for the Meso Foundation’s long-term financial stability and integrity and for governing the Foundation and setting its strategic direction and broad policy directives.

Lee Krug, MD, Chair  
Memorial Sloan Kettering Cancer Center
Michael Becich, MD, PhD  
University of Pittsburgh
Don Bendix  
Northridge, CA
General Steven Blum  
Reisterstown, MD
Melissa Culligan, RN  
University of Maryland
Faris Farasatti, PhD, PharmD  
University of Kansas Medical Center
Erica Iacono  
New York, NY
Shreya Kanodia, PhD  
Cedars-Sinai

Shelly Kozicki  
Grosse Ile, MI
Ted Lackner - Treasurer  
Delmar, NY
Terry Lynch  
International Association of Heat and Frost Insulators and Allied Workers
Leon Pendarvis  
Croton-on-Hudson, NY
Lew Phelps  
Los Angeles, CA
Sandy Robb  
Blue Springs, MO
Eric Witkin, Esq.  
Rye, NY

In Memoriam  
Congressman Bruce F. Vento

SCIENCE ADVISORY BOARD
Our Science Advisory Board (SAB) is comprised of clinicians and researchers who work within the mesothelioma field around the world. Members of the SAB are volunteers. They are expected to review and score the applications submitted for our research grants. They are also called upon for expert opinions and advice on scientific matters on behalf of the Meso Foundation.

H. Richard Alexander, MD, Chair  
University of Maryland Medical Center
Brad Black, MD  
Center for Asbestos Related Disease
Alain Borczuk, MD  
Columbia University
V. Courtney Broaddus, MD  
University of California San Francisco
Marc de Perrot, MD  
University Health Network
Stephen Hahn, MD  
Perelman School of Medicine at the University of Pennsylvania
Margaret Huflejt, PhD  
New York University, School of Medicine
Brooke Mossman, PhD  
University of Vermont College of Medicine
Luciano Mutti, MD, PhD  
Vercelli/Borgosesia Hospitals

Anna Nowak, PhD  
University of Western Australia
Jeremy Steele, MD  
St. Bartholomew’s Hospital
David Sugarbaker, MD  
Brigham & Womens Hospital
Anne S. Tsao, MD  
MD Anderson Cancer Center
Kiran Turaga, MD  
Medical College of Wisconsin
James Urbanic, MD  
UCSD Moores Comprehensive Cancer Center
Dennis A. Wigle, MD, PhD  
Mayo Clinic
Haining Yang, MD, PhD  
Cancer Research Center of Hawaii, University of Hawaii
Marjorie Zauderer, MD  
Memorial Sloan-Kettering Cancer Center
The following financial information is compiled from the Meso Foundation’s 2014 audited financial statements.

Total Assets: $2,883,896

### Public Support and Other Income

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Contributions</td>
<td>$1,689,278.00</td>
<td>$2,550,426</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$29,419.00</td>
<td>$99,214</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$1,718,697.00</strong></td>
<td><strong>$2,649,640</strong></td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$660,544</td>
<td>$987,213</td>
</tr>
<tr>
<td>Education, Support, Awareness</td>
<td>$906,471</td>
<td>$540,912</td>
</tr>
<tr>
<td>Advocacy</td>
<td>$81,697</td>
<td>$195,035</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$129,627</td>
<td>$202,244</td>
</tr>
<tr>
<td>Management</td>
<td>$301,159</td>
<td>$117,730</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$2,079,498</strong></td>
<td><strong>$2,043,134</strong></td>
</tr>
</tbody>
</table>

### ABOUT THE MESO FOUNDATION

The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to:

- Fund the highest quality and most promising mesothelioma research projects from around the world through our rigorous peer-reviewed process;
- Help mesothelioma patients connect with national mesothelioma experts and obtain the most up-to-date information on treatment options;
- Advocate in Washington D.C. for federal mesothelioma research funding to stop this national tragedy.

The Meso Foundation is a nationally-recognized nonprofit organization. Third-party charity evaluators have rated the Meso Foundation as a top charity for good governance, sound fiscal management and commitment to accountability and transparency. No other organization working within the field of mesothelioma has such credentials.

Charity Navigator awarded the Meso Foundation a 4-star (out of 4 stars) rating. Its Accountability & Transparency metrics, which account for 50 percent of a charity’s overall rating, reveal which charities have “best practices” that minimize the chance of unethical activities and whether they freely share basic information about their organization with their donors and other stakeholders.

The Meso Foundation is also accredited by the Better Business Bureau and the Independent Charities of America. More information about our most current accreditations is available at curemeso.org/accreditations.

The Foundation has been vetted by the National Cancer Institute (NCI) and is listed on their website as a resource.

In 2014, as a result of 65 positive reviews, GreatNonprofits rated the Meso Foundation as a Top-Rated Nonprofit.
The Mesothelioma Applied Research Foundation funds critically-needed research to eradicate mesothelioma as a life-ending disease. The Foundation’s Science Advisory Board (SAB) members, comprised of leading mesothelioma physicians and researchers from around the world, use their expertise to review and rank grant proposals submitted by their peers. Based on the funds generously donated to the Meso Foundation, the Board of Directors awards grants to the most promising projects.

In 2014, three grants were awarded, bringing the Meso Foundation’s total research funded to $9 million.

**Ravi Salgia, The University of Chicago**

**EPHA2 as A Novel Therapeutic Target in Malignant Pleural Mesothelioma**

In the U.S., approximately one in 100,000 people are diagnosed every year with malignant pleural mesothelioma (MPM). Median survival from the time of diagnosis is 9.2 months. Only one chemotherapeutic agent (pemetrexed) has been approved by the FDA for treatment of MPM. Thus, to make a significant impact on the therapy and overall survival for patients with MPM, newer biological mechanisms must be identified. Over-expression (a process that may cause cells to grow faster) of EPHA2 protein, a receptor of ephrin-A1 ligand, has been reported in many cancers. EPHA2 is associated with the growth and metastatic potential of tumors but the impact of abnormal EPHA2 on MPM patients/cell lines and the biological function/mechanism of EPHA2 in MPM is still uncertain.

Our initial study investigated these unknowns. Preliminary data showed that EPHA2 was found 66.7% (4/6) over-expressed in MPM cell lines and also in patient samples. 28% (11/39) of MPM patient samples had EPHA2 mutations (gene alteration). 10.3% (4/39) of MPM patient samples and 33% (2/6) of MPM cell lines had EPHA2 amplification (an increase in the frequency of replication of a DNA segment). Looking to the biological function/mechanism of EPHA2 in MPM, we found that cells with EPHA2 mutations grew faster and spread further than cells without EPHA2 mutations. Furthermore, cells with EPHA2 mutations had more resistance to cisplatin (a traditional chemotherapeutic agent). All of these initial findings suggest firstly, that EPHA2 is irregular in MPM and secondly, that EPHA2 is a potential biomarker (a traceable substance whose detection indicates a particular disease state) of MPM and could be used for better therapeutic strategy. We first propose to determine EPHA2 expression, amplification, and presence of mutation in MPM; correlate these variables with clinical parameters; and arrive at useful information regarding patients’ likely medical outcomes in MPM. Then, we will determine biological and biochemical functions with respect to EPHA2 and mutated EPHA2 in MPM. Finally, we will investigate the inhibition of EPHA2 in MPM cell lines and its effectiveness in combination with chemotherapies. We hope to use our improved understanding of EPHA2 mutations toward two ends: 1) to design effective therapies that target EPHA2 and 2) to identify the patient populations that will most benefit from this treatment.

**Tanguy Seiwert, The University of Chicago**

**The T-cell inflamed immune microenvironment in Malignant Mesothelioma**

Malignant Mesothelioma (MM) is a universally fatal cancer that arises from the mesothelial surfaces of the body, primarily the pleura, and the peritoneum. Current treatment consists of palliative cytotoxic chemotherapeutic agents namely cisplatin and pemetrexed. Benefit is limited and better treatment options, including modalities with lasting benefit and fewer side effects are urgently needed. It is well established that mesotheliomas are frequently infiltrated with immune cells of largely unknown function. The immune-microenvironment – specifically the potential presence of a tumor specific immune response, and presence of mechanisms of immune escape have not been adequately characterized to date. We have discovered that the inflamed phenotype in a subgroup of approximately one third of mesotheliomas closely resembles that observed in other tumor types (i.e. melanoma) where marked and lasting benefit from immune therapies such as PD-1 and PD-L1 checkpoint inhibitors is now established. Hence we will characterize in detail the inflamed phenotype present in this subgroup of mesotheliomas. We will use patient samples including from a clinical trial with the PD-1 checkpoint inhibitor pembrolizumab that is being initiated at the Univ. of Chicago in order to understand, which patients are most likely to benefit from immune therapies, and how to optimize such treatments.

**Travis Young, California Institute for Biomedical Research**

**Controllable CAR-T Therapy for Mesothelioma**

Cell-based therapies engineer a patient’s immune cells to seek and destroy tumor cells in the body. The therapies are incredibly potent and have cured many patients of blood cancers in clinical trials. However, with the potency of this therapy also comes dangerous side-effects including long-term immunosuppression and even death. Here, we propose a platform which adds safety to the potency of cell-based therapies. Already we have demonstrated this platform in the laboratory against many different diseases. In this proposal we will further develop this platform to target mesothelioma cells. Ultimately this therapy may provide a realistic hope for a cure for patients with mesothelioma.
In 2014, the Mesothelioma Applied Research Foundation continued growing its education and support services, and began the process of evaluating them and improving them as needed. To keep up with demand for services, the Foundation added a new staff member to focus specifically on patients’ (and their caregivers’ and families’) needs.

Mary Hesdorffer, APRN, Meso Foundation’s executive director and expert nurse practitioner, provides one-on-one medical consultations to:

- Identify a mesothelioma specialist if needed
- Review your treatment options to choose the best one for you
- Advise you regarding symptom-management and side-effects
- Understand the basics of the disease and the complex medical terms
- Connect with other mesothelioma patients
- Obtain financial aid

The Meso Foundation also provides:

- Support groups, including in-person, telephonic, and online
- National and regional conferences covering malignant mesothelioma
- ‘Meet the Mesothelioma Experts’ Live Interview Series
- Online and printed materials providing both education and support
- Support services for the bereaved community
ADVOCACY
2014 was an important year for the Meso Foundation’s advocacy efforts as we set the wheels in motion for much of our future activities.

In 2014, we focused on strengthening our relationships within the Department of Defense’s Congressionally-Directed Medical Research Program to ensure continued funding, which already awarded $8.8 million in mesothelioma research. As a result, additional funding was allocated through this program.

Early in the year, the Foundation joined the Deadliest Cancers Coalition, which is a collaboration of national non-profit organizations focused on addressing policy issues related to our nation’s most lethal, or recalcitrant, cancers, defined as those that have five-year relative survival rates below 50 percent. It was established in 2008 by the Pancreatic Cancer Action Network and other patient advocacy organizations and professional societies. Mesothelioma, with a survival rate of less than 10 percent at five years post diagnosis, fits this criterium.

Earlier in 2013, the Recalcitrant Cancer Act was passed by Congress directing the NCI to focus specifically on recalcitrant cancers defined as those with a five-year survival rate below 50 percent, and which have not seen substantial progress in the diagnosis or treatment. This is when the Meso Foundation saw an opportunity arise and attempted to add mesothelioma to the list of NCI’s focus cancers. On our behalf, Congresswomen Pingree and McCollum circulated among their congressional colleagues a Dear Colleague letter requesting support for adding mesothelioma to the Recalcitrant Cancer Act. In 2014, the Meso Foundation continued the push of garnering support which ultimately saw more than 20 representatives from both parties sign on. Although no other cancers were added to the act, through this process we gained valuable allies in the political sphere.

In March 2014, during the annual International Symposium on Malignant Mesothelioma, our community advocates took the stage by visiting their congressional representatives on Capitol Hill. In their ask, they addressed two issues. One was to add supporters to the Dear Colleague letter (discussed above), and the other was to continue and increase the Department of Defense medical research funding.

Over the year, collaborations took front and center as the Foundation signed on to several initiatives sponsored by groups such as the Coalition for Health Funding, the Ad Hoc Group for Medical Research, and the Friends of the Centers for Disease Control.

AWARENESS
In 2014, 45 community members organized 39 events raising funding and awareness of mesothelioma. Many of these events occurred concurrently with Mesothelioma Awareness Day, helping us gain critical momentum in visibility. In addition, Mary Hesdorffer, our executive director, participated in a media tour, whereby she gave radio and television interviews to over 20 programs, which promoted the Foundation as well as its programs and services.
Rev. Eric Linthicum received the Compassion Award.

Dr. Michele Carbone received the Pioneer Award.

Olga Pavlick and Sarah Pavlick received the Klaus Brauch Volunteer of the Year Award.

Anne Alessandrini of the Brigham and Women’s Hospital was the recipient of the June Breit and Jocelyn Farrar Outstanding Nurse Award.

Bruce Vento Hope Builder Award honored Congresswomen Pingree and McCollum.
$100,000 +
Law Offices of Peter G. Angelos
The Richard and Sandra Schulze Family Fund
Early, Lucarelli, Sweeney & Meisenkothen

$50,000 – 99,999
Levy, Phillips & Konigsberg, LLP

10,000 – 49,999
Aduro Biotech, Inc
Bonnie and John Anderson
Asbestos Workers Local 2
Joseph Belluck and Laura Aswad
Betty and Don Bendix
Ferraro & Associates, PA
Louis Fishbein
Gori, Julian & Associates, PC
Julie Gundlach and Daniel Young
Mary and Charles Hesdorffer
International Association of Heat & Frost
Insulators & Allied Workers
Jean and James Rion Endowment of Coastal
Community Foundation
J.R. Albert Foundation, Inc.
Shelly Kozicki
Ted Lackner
Patricia Lindsay
Hanne Mintz
Richard and Lora Mosca
Motley Rice, LLC

National Insulation Association
Owens Corning Corporation
ROD’s Benefit For Meso
Shrader & Associates
Simmons Hanly Conroy
Mark G Strauss

$5,000 – 9,999
Beate Barrett
Joan Brown
Geraldine Contrino
Creative Achievements
Sanjay Jin and Susan Critchfield
Zvi Eiref
Kayaking 4 Meso
Ted and Jennifer Gianaris
Kimberly and Todd Giardino
Johnson & Johnson - Matching Gifts Program
The Joseph Manzi Foundation
Kay Kaufman
Mary Morvant
The Kuwait American School
John and Jane Panza
Olga Pavlick
Ron and Jeannie Piekunka
Pinnacle Biologics, Inc.
Teresa Pounds
Race Roster
Ted and Susan Sherman
Janet Simkins
Enrico Sorrentino  
Hannelore Tucker  
Vanguard Charitable  
Bruce A Waite 5K Benefit Fund  
Timothy and Janet Zunk

$1,000 – 4,999

Barbara Madsen  
Mattaini Family Foundation  
Gloria McClain  
Paula McErlane  
Joel and Phyllis Miller  
Jennifer Miller Peters  
Nana Morelli  
Brooke Mossman  
Patricia Murray  
Mr. and Mrs. Henry J Nasella  
Rod Nash  
Joanne Naughton  
Joanna Nelson  
Sandra and David Neuenschwander  
Russell Norman  
Rosemary Patrick  
Ellen Patton  
Gary Paul  
Pepple, Johnson, et.al  
Lew Phelps  
Marion Pistoia  
Mary Plaisance  
Marilyn Porchetta  
Evelyn Roca  
Howard and Tenda Rosenblum  
Susan Rundle  
Rusty Clements Memorial Golf Tournament  
Theresa Rzepeka  
Bill Saffels  
Santa Margarita Catholic High School Breath of Hope Club  
Elaine and Michael Serling  
Maryann and Richard Shanas  
Nancy Silva  
Kenneth Smith  
Sara Solomon  
Karen Spracher  
Lorna Staples  
Peggy Sterling  
Jennifer Sutherland  
Nancy and John Tellor  
Suzanne Terman  
The Estate of Charlie Cole  
The John J Wright DVM Family Charitable Fund  
The Lanier Law Firm  
The Rucksdescel Law Firm, LLC  
The Williams Law Firm, P.C.

$500 – 999

A C & S Inc.  
Debra and David Acker  
Diane and Richard Allen  
Connie Andrus  
Ivan Angell  
Barbara Apking  
Pamela Baow  
Annette Barlow  
Jonathan Basinger  
Belluck & Fox, LLP  
Peggy Bergin  
Joel Berson  
Betsworth Bull Bash, LLC  
Erika Blumberg  
Boilermakers Local 40  
Carmel Bradbury  
Arnold Bressler  
Elizabeth Brining  
Craig and Angela Bullock  
Mike Burke  
Nancy Buszinski  
Carrollton Bank  
Dan & Mimi Cerniglia  
Lisa Chandler  
Kenneth and Maureen Charhut  
Rauch Family Charitable Foundation  
Margo Clements  
Mary Collins  
Commitment to Community  
Fran Conlin  
Cork Tree Creative, Inc.  
Cheri and Chuck Cusumano  
Bonnie Dahan  
DBA Good Cause Gifts  
Brian and Ashley Derrer  
Mary and Joanne Doolin  
David Ettinger  
Susan Fields  
Linda Fishbain  
Donna Frey  
Melanie Funsten  
General Electric Company  
Give With Liberty  
Ernest Guzman
Peter Hilditch
Edwin Holstein
John and Teresa Houser
Brenda Iannacone
IBM Employee Services Center
InFaith Community Foundation
International Brotherhood of Electrical Workers- Local 25
James C Ferrell, P.C.
Micheal Kinney
Elizabeth and Daniel Klein
Irene Klingemann
Venetia Kontogouris
Pamela Korte
Rose Kraemer
Ann and Paul Krouse
Kurowski Shultz, LLC.
Legacy Elementary School
Nadine and Israel Levy
Roger Lewis
Peter Liman
Verna Looker
David and Irene Luxenberg
Mahoney Family
Lynn Mahurin
Dan and Debbie McCoy
Timothy McDonnell
Diana McGuinness
Kathleen McLean
Microsoft Matching Gifts Program
Mills Family Foundation
Karen Morris
David Nash and Dawn Holbrook
Sherry Norman Davis
Oderzo Golf Club Friends
Micheal Tood and Lorie Pate
Ann Peters
Pamela Peters
Joe Petittas
Pohlman USA Court Reporting
Kenneth Prindle
Dolores Rampolla
Cynthia Reich
Klaus Rindt
Jeff Risse
Rita M Rodriguez
Lisa Rolfe
Carol and Raymond Rossi
Erica Ruble
Donna Saller
Brandon Schwulst
John F Shaw
Kimberly Snow-White
Ryan Solutions
Tern Stark
Russell Starr
Sy and Laurie Sternberg
Angela Sun
John and Marianne Surre
Elizabeth and Ronald Taylor
Diane Terpstra
The Bank
Millie and Bill Thomas, Sr.
Tri-S Supply
Irene Türckes
U-Jam Fitness
Jill and Lewis Vaughn
Joseph and Sabrina Vona
Kira Wakefield
Sarah Watson
William E Wenzel Jr
Whaleyville Animal Hospital, Inc
Joan White
Joy Whitney
Lindsay Wright
The Meso Foundation gratefully acknowledges the generosity and support of our 2013 Symposium sponsors.